setileuton (MK-0633) / Merck (MSD) - LARVOL DELTA

BEDB: a comprehensive binding energy database for molecular docking and dynamics: insights into Human Metapneumovirus (HMPV) Inhibitors. (PubMed, Database (Oxford)) - "MK-3207 and Etoposide exhibited docking scores of -10.3 and -9.6, respectively. Additional compounds, including Teniposide, UK432097, 85019940, Setileuton, Orvepitan, Cep-11981, Tadalafil, and VS-5584, were also analyzed, providing further insights into their binding mechanisms and potential therapeutic relevance. The database is developed using PHP, HTML, CSS, JavaScript, and Python and is freely accessible at https://www.pbed.habdsk.org/."

Journal

Unveiling the Anti-cancer Potential of Oxadiazole Derivatives: A Comprehensive Exploration of Structure-Activity Relationships and Chemico-Biological Insights. (PubMed, Med Chem) - "Overall, these results will prove to be a helpful and vital tool for medicinal chemists investigating and working with oxadiazoles for anti-cancer action."

Journal • Review • Oncology

The role and transformative potential of IL-19 in atherosclerosis. (PubMed, Cytokine Growth Factor Rev) - "Most antiatherosclerotic drugs in current clinical use, including atorvastatin and alirocumab, target hyperlipidemia. Several other drugs have also been investigated in clinical trials as anti-inflammatory agents; the development of some of these agents has been terminated (canakinumab, darapladib, varespladib, losmapimod, atreleuton, setileuton, PF-04191834, veliflapon, and methotrexate), but others remain in development (ziltivekimab, tocilizumab, Somalix, IFM-2427, anakinra, mesenchymal stem cells (MSCs), colchicine, everolimus, allopurinol, and montelukast)...We propose that IL-19 is a promising biomarker and target for the diagnosis and treatment of atherosclerosis. This review considers the role and mechanism of action of IL-19 in atherosclerosis and discusses whether IL-19 is a potential therapeutic target for this condition."

Journal • Review • Atherosclerosis • Cardiovascular • CNS Disorders • Dyslipidemia • Immunology • Inflammation • Multiple Sclerosis • Orthopedics

1,3,4-Oxadiazole Containing Compounds As Therapeutic Targets For Cancer Therapy. (PubMed, Mini Rev Med Chem) - "The discussion outlined herein will proved to be a helpful and vital tool for medicinal chemists investigating and working with 1,3,4-oxadiazoles and anticancer research programs."

Journal • Oncology

SARS-CoV-2 M inhibitors: identification of anti-SARS-CoV-2 M compounds from FDA approved drugs. (PubMed, J Biomol Struct Dyn) - "Based on comparative molecular simulation and interaction profiling of the screened drugs with SARS-CoV-2 M revealed R428 (-10.5 kcal/mol), Teniposide (-9.8 kcal/mol), VS-5584 (-9.4 kcal/mol), and Setileuton (-8.5 kcal/mol) with stronger stability and affinity than other drugs and N3 inhibitor; and hence, these drugs are advocated for further validation using in vitro enzyme inhibition and in vivo studies against SARS-CoV-2 infection."

FDA event • Journal • Infectious Disease • Novel Coronavirus Disease

5-Lipoxygenase as a drug target: A review on trends in inhibitors structural design, SAR and mechanism based approach. (PubMed, Bioorg Med Chem) - "Currently, the only drug against 5-LOX which is available is Zileuton, while a few inhibitors are in clinical trial stages such as Atreleuton and Setileuton. So, there is a dire requirement in the area of progress of novel 5-LOX inhibitors which necessitates an understanding of their structure activity relationship and mode of action. In this review, novel 5-LOX inhibitors reported so far, their structural design, SAR and developmental strategies along with clinical updates are discussed over the last two decades."

Journal • Review • Allergy • Asthma • Atherosclerosis • Cardiovascular • Dyslipidemia • Immunology • Inflammation • Respiratory Diseases